Sunday 18 October 2026
Export IMMP’s income statement to Excel — free account
Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
3.20
0.01
−0.31%
Follow IMMP
| Dec '25 | Dec '24 | Dec '23 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.89 | 18.03 | 16.75 | — | |
Current Ratio |
2.97 | 18.86 | 17.24 | — | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | — | |
Debt/Assets |
0.34% | 0.57% | 0.00% | — | |
Debt/Equity |
0.01 | 0.01 | 0.00 | — | |
Asset Turnover |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.07 | — | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(18.87) | (18.61) | (0.01) | — | |
Working Capital |
60.92 | 107.21 | 69.38 | — | |
Capital Expenditures |
(0.06) | (0.01) | (0.01) | — | |
Net Current Asset Value |
60.07 | 106.79 | 68.35 | — | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
13.91 | 4.17 | 3.61 | — | |
Average Payables |
17.58 | 4.13 | 3.15 | — | |
Average Assets |
92.11 | 87.36 | 55.02 | — | |
Average Common Equity |
72.13 | 78.38 | 47.26 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026